EULAR

Analyze the Clinical Trial Landscape Through the Pharma Competitive Intelligence Monitoring Services by DelveInsight

Retrieved on: 
Thursday, January 18, 2024

LAS VEGAS, Jan. 18, 2024 /PRNewswire/ -- DelveInsight, a leading pharma competitive intelligence and consulting solutions company, offers dynamic Pharma Competitive Intelligence Monitoring Services. Through this service, clients can easily monitor developmental assets, clinical trials, regulatory milestones, commercial news, and receive high-priority alerts in real time as well as assess updates via an online dashboard. 

Key Points: 
  • LAS VEGAS, Jan. 18, 2024 /PRNewswire/ -- DelveInsight, a leading pharma competitive intelligence and consulting solutions company, offers dynamic Pharma Competitive Intelligence Monitoring Services .
  • Competitive intelligence monitoring enables companies to swiftly adjust to market fluctuations, comprehend patient needs, address developmental challenges, enhance their overall decision-making processes, and leverage competitive advantage.
  • Demonstrating proficiency in Competitive Intelligence Monitoring, DelveInsight assists clients in fortifying their brand's market standing and company's overall positioning, staying abeam of prevailing industry trends.
  • Leverage our Competitive Intelligence Monitoring Services for precise and effective results:
    Monitor competitors extensively; who are in product development, or those already in the market
    Ask for a proposal to find out how DelveInsight's pharma Competitive intelligence monitoring solutions can assist you.

Analyze the Clinical Trial Landscape Through the Pharma Competitive Intelligence Monitoring Services by DelveInsight

Retrieved on: 
Thursday, January 18, 2024

LAS VEGAS, Jan. 18, 2024 /PRNewswire/ -- DelveInsight, a leading pharma competitive intelligence and consulting solutions company, offers dynamic Pharma Competitive Intelligence Monitoring Services. Through this service, clients can easily monitor developmental assets, clinical trials, regulatory milestones, commercial news, and receive high-priority alerts in real time as well as assess updates via an online dashboard. 

Key Points: 
  • LAS VEGAS, Jan. 18, 2024 /PRNewswire/ -- DelveInsight, a leading pharma competitive intelligence and consulting solutions company, offers dynamic Pharma Competitive Intelligence Monitoring Services .
  • Competitive intelligence monitoring enables companies to swiftly adjust to market fluctuations, comprehend patient needs, address developmental challenges, enhance their overall decision-making processes, and leverage competitive advantage.
  • Demonstrating proficiency in Competitive Intelligence Monitoring, DelveInsight assists clients in fortifying their brand's market standing and company's overall positioning, staying abeam of prevailing industry trends.
  • Leverage our Competitive Intelligence Monitoring Services for precise and effective results:
    Monitor competitors extensively; who are in product development, or those already in the market
    Ask for a proposal to find out how DelveInsight's pharma Competitive intelligence monitoring solutions can assist you.

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Retrieved on: 
Monday, November 13, 2023

“It’s important that we saw both early and large reductions in proteinuria,” said Dr.

Key Points: 
  • “It’s important that we saw both early and large reductions in proteinuria,” said Dr.
  • Results are comparable to those observed in the Phase 3 AURORA1 study of voclosporin (ORR 70% at 6 and 12 months in active treatment).
  • Consistent with the decline in UPCR overtime, subjects were able to taper their systemic corticosteroids over the course of the study.
  • The poster presentation is available on the Presentations page of Equillium’s website under the Lupus tab.

AMGEN PRESENTS NEW DATA FROM PHASE 2 TRIAL OF DAZODALIBEP IN SJÖGREN'S SYNDROME AT ACR 2023

Retrieved on: 
Tuesday, November 7, 2023

THOUSAND OAKS, Calif., Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from its Phase 2 study evaluating dazodalibep, an investigational medicine, for the treatment of Sjögren's. These results will be featured in presentations at the American College of Rheumatology (ACR) Convergence 2023, Nov. 10-15, in San Diego. Findings from the study demonstrate that dazodalibep may improve both the systemic and symptomatic disease burden of two different patient populations.

Key Points: 
  • THOUSAND OAKS, Calif., Nov. 7, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from its Phase 2 study evaluating dazodalibep, an investigational medicine, for the treatment of Sjögren's.
  • These results will be featured in presentations at the American College of Rheumatology (ACR) Convergence 2023, Nov. 10-15, in San Diego.
  • Findings from the study demonstrate that dazodalibep may improve both the systemic and symptomatic disease burden of two different patient populations.
  • In May 2023, presentations at the 2023 EULAR Congress reported that at Day 169, both patient groups treated with dazodalibep achieved the study's primary endpoint.

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Retrieved on: 
Monday, November 6, 2023

“The presentation at ASN represents current data from the EQUALISE study, which includes all but the last patient in the follow up period,” said Bruce Steel, chief executive officer at Equillium.

Key Points: 
  • “The presentation at ASN represents current data from the EQUALISE study, which includes all but the last patient in the follow up period,” said Bruce Steel, chief executive officer at Equillium.
  • “We are encouraged that we continue to see clinically meaningful response rates, particularly in these highly proteinuric subjects.
  • Results are comparable to those observed in the Phase 3 AURORA1 study of voclosporin (ORR 70% at 6 and 12 months in active treatment).
  • Consistent with the decline in UPCR overtime, subjects were able to taper their systemic corticosteroids over the course of the study.

Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis

Retrieved on: 
Thursday, October 26, 2023

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) – Aurinia welcomes the 2023 updated recommendations from The European Alliance of Associations for Rheumatology (EULAR) for the management of systemic lupus erythematosus (SLE) based on emerging new evidence, including a new treatment paradigm for lupus nephritis (LN).

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) – Aurinia welcomes the 2023 updated recommendations from The European Alliance of Associations for Rheumatology (EULAR) for the management of systemic lupus erythematosus (SLE) based on emerging new evidence, including a new treatment paradigm for lupus nephritis (LN).
  • The new recommendations suggest that in addition to traditional anchor drugs, therapies including LUPKYNIS® (voclosporin) should be considered for any active class of lupus nephritis.
  • “Aurinia appreciates EULAR’s thoughtful consideration for improving the management of lupus nephritis with recommendations that reflect therapeutic advancements in this underserved patient population.
  • The updated recommendations reflect the growing recognition of the clinical value that a therapy like voclosporin provides to people living with lupus nephritis.

Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics

Retrieved on: 
Thursday, August 17, 2023

WATERTOWN, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.

Key Points: 
  • As part of this initiative, the Company plans to:
    Continue to Advance SEL-212 in Patients with Chronic Refractory Gout in Partnership with Sobi.
  • The decrease was primarily the result of the capital prioritization initiative that was enacted in the second quarter of 2023.
  • Net (Loss) Income: For the second quarter of 2023, Selecta reported net loss of $11.4 million, or basic net loss per share of $(0.07).
  • Selecta’s management will host a conference call at 8:30 AM ET today to provide a corporate update and review the Company’s second quarter 2023 financial results and strategic updates.

Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 10, 2023

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.

Key Points: 
  • Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.
  • The complete MISSION Phase 1b/2 results were presented as an oral presentation at the LUPUS & KCR 2023 meeting, which took place May 17-20, 2023 in Seoul, Korea.
  • Research and development expenses for the second quarter of 2023 increased by $9.7 million to $21.0 million compared to $11.3 million in the second quarter of 2022.
  • General and administrative (G&A) expenses for the second quarter of 2023 increased by $0.8 million to $5.8 million compared to $5.0 million in the second quarter of 2022.

Xencor Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a review of recent business and clinical highlights.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2023 and provided a review of recent business and clinical highlights.
  • In the second quarter of 2023, Xencor earned $11.2 million of royalty revenue from Alexion on net sales of Ultomiris.
  • Decreased net loss in the second quarter of 2023 compared to 2022 is primarily due to additional income and interest earned.
  • ET (1:30 p.m. PT) to discuss the second quarter 2023 financial results and provide a corporate update.

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results

Retrieved on: 
Thursday, August 3, 2023

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and six months ended June 30, 2023.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and six months ended June 30, 2023.
  • Financial Results for the Three and Six Months Ended June 30, 2023
    Total net revenue was $41.5 million and $28.2 million for the three months ended June 30, 2023 and June 30, 2022, respectively.
  • Interest expense was $0.1 million for the three and six months ended June 30, 2023 due to the commencement of the monoplant finance lease during the second quarter of 2023.
  • Aurinia will host a conference call and webcast to discuss the quarter ended June 30, 2023 financial results today, Thursday, August 3, 2023 at 8:30 a.m.